#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12552	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2558	593.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1990	1990	T	830	T,C,G,A	827,1,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12552	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2558	593.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1724	1724	C	830	C	830	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21188	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4066	649.4	0	.	n	.	0	C543T	SNP	543	543	C	1115	1115	T	825	T,C,G	822,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21188	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4066	649.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1909	1909	A	843	A,C,T	840,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21188	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4066	649.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2543	2543	C	705	C,T,G	703,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21188	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4066	649.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2617	2617	A	652	A,T	650,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21188	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4066	649.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3169	3169	C	725	C,G	724,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	1998	folP	855	855	99.88	folP.l15.c17.ctg.1	1967	126.6	1	SNP	p	R229S	1	R229S	NONSYN	685	687	CGC	1238	1240	AGC	198;196;196	A;G;C	198;196;196	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4750	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3927	150.9	0	.	p	.	0	V290I	NONSYN	868	870	GTT	1502	1504	ATT	191;193;195	A;T,A;T,A	191;192,1;194,1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4750	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3927	150.9	1	SNP	p	S91F	0	.	.	271	273	TCC	905	907	TCC	174;176;172	T,G;C;C	172,2;176;172	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4750	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3927	150.9	1	SNP	p	D95N	0	.	.	283	285	GAC	917	919	GAC	176;173;173	G;A;C	176;173;173	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4750	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3927	150.9	1	SNP	p	D95G	0	.	.	283	285	GAC	917	919	GAC	176;173;173	G;A;C	176;173;173	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	1830	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1881	121.0	1	SNP	p	G45D	1	.	.	133	135	GAC	871	873	GAC	213;214;217	G;A;C	213;214;217	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1028	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1490	86.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3541	157.2	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1844	1846	GCA	218;219;218	G;C;A	217;218;217	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3541	157.2	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2327	2329	ATT	224;221;220	A,C,G;T,A,C;T	219,4,1;219,1,1;220	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3541	157.2	1	SNP	p	D86N	0	.	.	256	258	GAC	797	799	GAC	190;193;192	G;A,C;C	190;192,1;192	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3541	157.2	1	SNP	p	S87W	0	.	.	259	261	AGT	800	802	AGT	193;195;195	A;G;T	193;195;195	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3541	157.2	1	SNP	p	S87R	0	.	.	259	261	AGT	800	802	AGT	193;195;195	A;G;T	193;195;195	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3541	157.2	1	SNP	p	S87I	0	.	.	259	261	AGT	800	802	AGT	193;195;195	A;G;T	193;195;195	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3541	157.2	1	SNP	p	S88P	0	.	.	262	264	TCC	803	805	TCC	195;197;199	T;C;C	195;197;199	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3956	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3171	155.4	0	.	p	.	0	H611N	NONSYN	1831	1833	CAC	2370	2372	AAC	203;203;206	A;A,T,G,C;C	203;200,1,1,1;206	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3956	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3171	155.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1767	1769	GGC	217;212;210	G,A;G;C,A	216,1;212;209,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	A438V	NONSYN	1312	1314	GCA	1942	1944	GTC	205;206;206	G;T;C	205;206;206	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	V444E	NONSYN	1330	1332	GTT	1960	1962	GAA	197;196;192	G,A,T;A;A	195,1,1;196;192	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	L448V	NONSYN	1342	1344	CTC	1972	1974	GTC	196;195;196	G;T;C	196;195;196	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	Q458K	NONSYN	1372	1374	CAA	2002	2004	AAA	189;190;191	A;A;A,T	189;190;190,1	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	I462V	NONSYN	1384	1386	ATA	2014	2016	GTC	187;187;185	G;T,C;C	187;186,1;185	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	F463I	NONSYN	1387	1389	TTC	2017	2019	ATC	186;185;185	A,C;T,G;C	185,1;184,1;185	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	E465A	NONSYN	1393	1395	GAA	2023	2025	GCC	187;188;188	G,T;C,A;C	186,1;186,2;188	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	R469K	NONSYN	1405	1407	CGC	2035	2037	AAA	190;192;191	A,C;A;A	189,1;192;191	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	E470K	NONSYN	1408	1410	GAG	2038	2040	AAA	193;196;197	A;A;A	193;196;197	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	N473E	NONSYN	1417	1419	AAT	2047	2049	GAG	197;197;197	G;A,C;G,T	197;196,1;196,1	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	N513Y	NONSYN	1537	1539	AAC	2167	2169	TAC	167;166;167	T;A;C	167;166;167	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	G517A	NONSYN	1549	1551	GGT	2179	2181	GCC	165;166;170	G;C,G;C,T	165;165,1;169,1	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	0	.	p	.	0	A550T	NONSYN	1648	1650	GCA	2278	2280	ACA	188;190;192	A;C;A	188;190;192	.	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1561	1563	GCA	187;187;187	G;C;A	187;187;187	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1564	1566	ATC	187;189;189	A;T;C,T	187;189;188,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1576	1578	GTG	195;196;200	G;T;G	195;196;200	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1576	1578	GTG	195;196;200	G;T;G	195;196;200	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2134	2136	GCG	184;186;188	G;C;G	184;186;188	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2134	2136	GCG	184;186;188	G;C;G	184;186;188	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2257	2259	GGT	189;189;187	G;G;T	189;189;187	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2266	2268	GGC	186;184;183	G;G;C,A	186;184;181,2	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	3434	penA	1752	1752	95.66	penA.l15.c17.ctg.1	2939	145.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2284	2286	CCG	199;203;205	C;C;G	199;203;205	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4918	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3550	172.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2320	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2242	128.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	768	768	C	189	C	189	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	18;21;27	T;T;A	18;21;27	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	69;69;69	C,A;A;T	68,1;69;69	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	69;69;69	A;G;T	69;69;69	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	69;69;69	T;A;C	69;69;69	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	R307E	NONSYN	919	921	AGA	161	163	GAA	1;1;1	G;A;A	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	1;1;1	A;T;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	1;1;1	T;C;G	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	1;1;1	G;C;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	1;1;1	A;G;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	1;1;1	G;C;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	304	porB1a	984	226	90.71	porB1a.l15.c30.ctg.1	353	33.5	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	1;1;1	G;T;T	1;1;1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2578	porB1b	1035	1035	98.85	porB1b.l6.c30.ctg.1	2014	159.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	938	940	GGA	214;215;215	G;G,T,C;A	214;213,1,1;215	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2578	porB1b	1035	1035	98.85	porB1b.l6.c30.ctg.1	2014	159.4	0	.	p	.	0	.	INDELS	629	630	AA	1141	1143	TAG	213;213;207	T;A,T;G	213;212,1;207	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2578	porB1b	1035	1035	98.85	porB1b.l6.c30.ctg.1	2014	159.4	0	.	p	.	0	.	MULTIPLE	631	633	TAC	1145	1148	CAAT	205;208;208;208	C;A;A;T	205;208;208;208	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2578	porB1b	1035	1035	98.85	porB1b.l6.c30.ctg.1	2014	159.4	0	.	p	.	0	N212fs	FSHIFT	634	634	A	1150	1150	T	212	T,G	210,2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2578	porB1b	1035	1035	98.85	porB1b.l6.c30.ctg.1	2014	159.4	1	SNP	p	G120K	0	.	.	358	360	GGT	869	871	GGT	204;204;204	G;G;T	204;204;204	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2578	porB1b	1035	1035	98.85	porB1b.l6.c30.ctg.1	2014	159.4	1	SNP	p	A121D	0	.	.	361	363	GCC	872	874	GCC	204;204;204	G,T;C;C	202,2;204;204	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2578	porB1b	1035	1035	98.85	porB1b.l6.c30.ctg.1	2014	159.4	1	SNP	p	A121N	0	.	.	361	363	GCC	872	874	GCC	204;204;204	G,T;C;C	202,2;204;204	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	8630	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5372	200.4	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2245	2247	CAT	245;247;247	C,A;A;T	244,1;247;247	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1252	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1494	104.4	1	SNP	p	V57M	0	.	.	169	171	GTG	730	732	GTG	228;228;227	G;T;G	228;228;227	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
